IT1397867B1 - Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso - Google Patents

Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso

Info

Publication number
IT1397867B1
IT1397867B1 ITFI2010A000013A ITFI20100013A IT1397867B1 IT 1397867 B1 IT1397867 B1 IT 1397867B1 IT FI2010A000013 A ITFI2010A000013 A IT FI2010A000013A IT FI20100013 A ITFI20100013 A IT FI20100013A IT 1397867 B1 IT1397867 B1 IT 1397867B1
Authority
IT
Italy
Prior art keywords
liposomas
prostaglandine
pge1
formulations
contain
Prior art date
Application number
ITFI2010A000013A
Other languages
English (en)
Inventor
Giovanni Brotzu
Original Assignee
Brotzu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ITFI2010A000013A priority Critical patent/IT1397867B1/it
Application filed by Brotzu filed Critical Brotzu
Priority to US13/574,426 priority patent/US20130039975A1/en
Priority to EP11709472.2A priority patent/EP2531222B1/en
Priority to ES11709472.2T priority patent/ES2477233T3/es
Priority to DK11709472.2T priority patent/DK2531222T3/da
Priority to CN201180007198.0A priority patent/CN102811745B/zh
Priority to CA2787725A priority patent/CA2787725A1/en
Priority to PCT/IB2011/050463 priority patent/WO2011095938A1/en
Priority to BR112012019344A priority patent/BR112012019344A2/pt
Publication of ITFI20100013A1 publication Critical patent/ITFI20100013A1/it
Application granted granted Critical
Publication of IT1397867B1 publication Critical patent/IT1397867B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ITFI2010A000013A 2010-02-03 2010-02-03 Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso IT1397867B1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ITFI2010A000013A IT1397867B1 (it) 2010-02-03 2010-02-03 Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
EP11709472.2A EP2531222B1 (en) 2010-02-03 2011-02-03 Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use
ES11709472.2T ES2477233T3 (es) 2010-02-03 2011-02-03 Liposomas que contienen prostaglandina E1 (PGE1), formulaciones que los contienen y su uso
DK11709472.2T DK2531222T3 (da) 2010-02-03 2011-02-03 Liposomer indeholdende prostaglandin e1 (pge1), formuleringer indeholdende dem og deres anvendelse
US13/574,426 US20130039975A1 (en) 2010-02-03 2011-02-03 Liposomes Containing Prostaglandin E1 (PGE1), Formulations Containing Them and Their Use
CN201180007198.0A CN102811745B (zh) 2010-02-03 2011-02-03 包含前列腺素e1(pge1)的脂质体,包含它们的制剂及它们的应用
CA2787725A CA2787725A1 (en) 2010-02-03 2011-02-03 Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use
PCT/IB2011/050463 WO2011095938A1 (en) 2010-02-03 2011-02-03 Liposomes containing prostaglandin e1 (pge1), formulations containing them and their use
BR112012019344A BR112012019344A2 (pt) 2010-02-03 2011-02-03 lipossomas contendo prostaglandina e1 (pge1) formulações que os contem e sua aplicação

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITFI2010A000013A IT1397867B1 (it) 2010-02-03 2010-02-03 Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso

Publications (2)

Publication Number Publication Date
ITFI20100013A1 ITFI20100013A1 (it) 2011-08-04
IT1397867B1 true IT1397867B1 (it) 2013-02-04

Family

ID=42357658

Family Applications (1)

Application Number Title Priority Date Filing Date
ITFI2010A000013A IT1397867B1 (it) 2010-02-03 2010-02-03 Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso

Country Status (9)

Country Link
US (1) US20130039975A1 (it)
EP (1) EP2531222B1 (it)
CN (1) CN102811745B (it)
BR (1) BR112012019344A2 (it)
CA (1) CA2787725A1 (it)
DK (1) DK2531222T3 (it)
ES (1) ES2477233T3 (it)
IT (1) IT1397867B1 (it)
WO (1) WO2011095938A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20120036A1 (it) * 2012-02-02 2013-08-03 Robert Davis Steigerwalt Jr Applicazione transdermica di prostaglandina e1 per il trattamento dell¿ischemia oculare.
ITFI20120092A1 (it) * 2012-05-14 2013-11-15 Giovanni Brotzu Liposomi contenenti prostaglandina e1 (pge1) ed un estrogeno vegetale, formulazioni per uso topico che li contengono e loro uso.
SI3145490T1 (sl) 2014-05-06 2018-09-28 Fidia Farmaceutici S.P.A. Liposomi, ki vsebujejo di-homo-gama linolensko kislino (dgla), formulacije, ki vsebujejo le-te in njihova uporaba
CN107049942A (zh) * 2016-12-30 2017-08-18 北京普德康利医药科技发展有限公司 一种前列地尔注射液
IT201700059875A1 (it) * 2017-05-31 2018-12-01 Univ Degli Studi Cagliari Complessi a base di fosfolipidi, fibre idrosolubili e principi attivi antiossidanti di origine naturale, loro preparazione e uso in formulazioni orali

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4661105A (en) * 1981-06-29 1987-04-28 Alza Corporation Medical bandage for administering vasodilator drug
US4846826A (en) * 1981-07-22 1989-07-11 Alza Corporation Method for treating ischemic conditions
US5811118A (en) * 1987-05-22 1998-09-22 The Liposome Company, Inc. Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations
AU617678B2 (en) * 1987-05-22 1991-12-05 Liposome Company, Inc., The Prostaglandin-lipid formulations
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
ITRM20010708A1 (it) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile.

Also Published As

Publication number Publication date
BR112012019344A2 (pt) 2019-09-24
ITFI20100013A1 (it) 2011-08-04
CN102811745B (zh) 2015-07-01
DK2531222T3 (da) 2014-06-23
CN102811745A (zh) 2012-12-05
ES2477233T3 (es) 2014-07-16
EP2531222A1 (en) 2012-12-12
CA2787725A1 (en) 2011-08-11
WO2011095938A1 (en) 2011-08-11
US20130039975A1 (en) 2013-02-14
EP2531222B1 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
SMT201600226B (it) Alcune amminopirimidine, loro composizioni e metodi per il loro uso
DK3175711T3 (da) Parasitiske sammensætninger indeholdende multiple aktivstoffer, fremgangsmåder og anvendelser deraf
BR112012031232A2 (pt) método, dispositivo e uso
DK2648809T3 (da) Naturlige formuleringer
FI20105860A0 (fi) Aktiivinen paikannusjärjestelmä
DK3091029T5 (da) Anti-IL13-antistofformuleringer
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
IT1398930B1 (it) Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
UA22448S (uk) Печиво
BR302012001179S1 (pt) "configuração aplicada em farol"
DK2455322T3 (da) Kran
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
DK2468677T3 (da) Stablekran
DK2390884T3 (da) Superledende magnetiseringsanordning
BR112013019687A2 (pt) antraquinona contendo preparações/formulações de lignina.
IT1397867B1 (it) Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso
ITTO20111220A1 (it) Composizione contenente un fosfato di tocoferolo e procedimento di preparazione.
DK2402077T3 (da) Isolatorenhed
FR2958500B1 (fr) Preparation insecticide, insectifuge, ovicide, larvicide, nymphicide
BR302012001168S1 (pt) "configuração aplicada em farol"
DK2571902T3 (da) Ny fremgangsmåde
DE112011102273A5 (de) Roboterstruktur
DE112012003594A5 (de) Aktive Plattform-Vorrichtung